title: New Surfactant-based Dressing Product to Improve Wound Closure Rates of Nonhealing Wounds: A European Multicenter Study Including 1036 Patients.
abstract: OBJECTIVE
  A new surfactant-based biomaterial containing the antimicrobial 1% silver sulfadiazine (SSD) was developed at the University of Virginia (Charlottesville, VA) to improve outcomes for nonhealing wounds. This study's objective was to clinically test the wound care outcomes of the new surfactant-based antimicrobial wound dressing (SAWD) in a multicenter trial.
  
  
  METHODS
  This cohort study enrolled 1036 patients with any nonhealing wound of > 3 months duration not responding to standard-of-care treatments from 10 wound care centers in 7 European countries. The SAWD was used for all wound types at all stages of complexity, healing, and severity. Data collection ranged from 6 months to 2 years and measured the percentage of patients achieving wound closure and time to complete closure.
  
  
  RESULTS
  Of the 1036 patients, 70% achieved wound closure, 24.6% were still in treatment at data collection, and 5.4% had a therapy change. The majority (56%) of these non-healing wounds achieved wound closure within 11 weeks. Patients were treated with the SAWD for 3 weeks to more than 1 year with no complications or adverse effects from long-term SSD antimicrobial use.
  
  
  CONCLUSIONS
  Ten centers concluded that the new SAWD provided positive results (improved wound closure rates, reduction of inflammation, pain, and odor), improvements in clinical application (faster and easier dressing change), and improved patient compliance.
authors.affiliation: Azienda Ospedaliera Universitaria, Policlinico Paolo Giaccone di Palermo, Department of Geriatric Surgery, Palermo, Sicily, Italy.
authors.forename: Francesco Paolo
authors.initials: FP
authors.lastname: Palumbo
authors.affiliation: Wound Healing School of Medicine, Cardiff University, Cardiff, UK.
authors.forename: Keith G
authors.initials: KG
authors.lastname: Harding
authors.affiliation: Vascular Surgery Unit, A.O.G. Salvini, Garbagnate Milanese, Italy.
authors.forename: Franca
authors.initials: F
authors.lastname: Abbritti
authors.affiliation: Wound Healing School of Medicine, Cardiff University, Cardiff, UK.
authors.forename: Sarah
authors.initials: S
authors.lastname: Bradbury
authors.affiliation: Ambulatorien der Steiermärkischen Gebietskrankenkasse, Fachärztezentrum Graz, Austria.
authors.forename: Jürgen Dietmar
authors.initials: JD
authors.lastname: Cech
authors.affiliation: Wound Healing School of Medicine, Cardiff University, Cardiff, UK.
authors.forename: Nicola
authors.initials: N
authors.lastname: Ivins
authors.affiliation: Diabetologe DDG, Wound Care Centre, Städt Krankenhaus Offenbach, Germany.
authors.forename: Dieter
authors.initials: D
authors.lastname: Klein
authors.affiliation: Private Practice, Specialist in Dermatologie und Venerologie, Wien, Austria.
authors.forename: Gabrielle
authors.initials: G
authors.lastname: Menzinger
authors.affiliation: Wound Care Centre, AZ St. Elisabeth Zottegem and Wondzorg De Parel Zorg-en Dienstencentrum, Hillegem, Belgium.
authors.forename: Frans
authors.initials: F
authors.lastname: Meuleneire
authors.affiliation: Vulnologic Center and Second Unit of General Surgery, Villa Fiorita Surgical Clinic, Prato, Italy.
authors.forename: Simone
authors.initials: S
authors.lastname: Seratoni
authors.affiliation: Ambulatorien der Steiermärkischen Gebietskrankenkasse, Fachärztezentrum Graz, Austria.
authors.forename: Christoph
authors.initials: C
authors.lastname: Zölß
authors.affiliation: Clinic for Cardiovascular Surgery, University Hospital of Zurich, Zurich, Switzerland.
authors.forename: Dieter
authors.initials: D
authors.lastname: Mayer
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001458:Bandages; D001672:Biocompatible Materials; D002908:Chronic Disease / Q000628:therapy; D015331:Cohort Studies; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D012837:Silver Sulfadiazine / Q000494:pharmacology* / Q000627:therapeutic use*; D013501:Surface-Active Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*; D014946:Wound Infection / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000890:Anti-Infective Agents; D001672:Biocompatible Materials; D013501:Surface-Active Agents; D012837:Silver Sulfadiazine